|
The following article is part of convention protection from the American Association of Clinical Endocrinology Annual Meeting 2021: ENVISION, being held nearly from May 26 to May 29, 2021. The staff at Endocrinology Advisor can be reporting on the newest information and analysis carried out by main specialists within the area. Check again for extra from the AACE Annual Meeting 2021: ENVISION. |
Semaglutide plus intensive behavioral remedy was discovered to be related to substantial, sustained, and clinically related imply weight reduction in contrast with placebo in chubby or overweight adults with out kind 2 diabetes, in response to analysis offered on the thirtieth Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (ENVISION 2021).
Continue Reading
In a submit hoc subgroup evaluation of the STEP 3 trial (ClinicalTrials.gov Identifier: NCT03611582), investigators sought to find out whether or not members’ baseline traits and weight historical past would have an effect on weight reduction with semaglutide, a glucagon-like peptide-1 receptor agonist, in contrast with placebo plus intensive behavioral remedy. Adults with out kind 2 diabetes and with weight problems or who had been chubby and had 1 or extra weight-related comorbidity had been randomly assigned 2:1 to intensive behavioral remedy plus both once-weekly semaglutide 2.4 mg administered subcutaneously or placebo for 68 weeks. Weight loss distribution was assessed in 498 members who had been on therapy and had a physique weight measurement at week 68; 334 members had been within the semaglutide group and 164 had been within the placebo group.
The examine authors analyzed imply weight reduction proportion in response to subgroups of baseline traits and weight historical past with use of a blended mannequin for repeated measurements within the general cohort from STEP 3. Participants had been categorized in response to baseline age, intercourse, race, ethnicity, physique weight, physique mass index (BMI), and weight historical past obtained from a self-report questionnaire.
Participants’ general imply age was 46 years (81% girls), with a imply physique weight of 105.8 kg and a imply BMI of 38.0 kg/m2.
The researchers discovered higher proportions of sufferers handled with semaglutide within the larger weight loss classes in contrast with those that acquired placebo. Participants with at the very least a 20% weight reduction included 38.6% of the semaglutide group in contrast with 4.3% of the placebo group. Participants who had 15% to lower than 20% weight reduction included 21% of the semaglutide group and eight.5% of the placebo group.
At week 68, the imply proportion of weight reduction was considerably higher in sufferers who used semaglutide in contrast with placebo relating to all baseline medical attribute subgroups together with age, intercourse, race, ethnicity, physique weight, and BMI (P <.01 for therapy variations).
The imply proportion of weight reduction was considerably higher amongst those that acquired semaglutide vs placebo in all subgroups outlined by weight historical past: age of onset, most pretrial-to-trial baseline weight, weight biking, and household historical past (P <.01 for therapy variations). Similar therapy results had been discovered among the many weight-history subgroups, with semaglutide therapy main with 15.2% to 18.8% weight reduction at week 68 in contrast with 2.7% to 7.6% with placebo.
No important subgroup interactions had been noticed for any parameter apart from BMI (interplay P =.01 for BMI, P >.05 for all different parameters).
“Clinical baseline traits and weight historical past had minimal results on weight reduction with semaglutide, suggesting potential advantages of this therapy for a variety of individuals with chubby or weight problems,” the investigators concluded.
Disclosures: The trial was sponsored by Novo Nordisk. One of the authors of the summary of the poster is affiliated with Novo Nordisk A/S. Please see the unique reference for a full record of disclosures.
|
Visit Endocrinology Advisor‘s conference section for full protection from the AACE Annual Meeting 2021: ENVISION. |
Reference
Garvey WT, Hesse D, Holst-Hansen T, et al. Once-weekly subcutaneous semaglutide 2.4 mg plus intensive behavioral remedy produces clinically significant weight reduction in adults with chubby/weight problems no matter baseline traits and weight historical past. Presented at: 2021 AACE Virtual Annual Meeting, May 26-29, 2021.
